Retatrutide vs tirzepatide vs semaglutide is the comparison metabolic researchers are searching for most in 2026. These three compounds sit on one scientific ladder, moving from one hormone receptor to two and then to three. Each step has produced larger average weight loss in published trials. This retatrutide vs tirzepatide vs semaglutide guide explains how the receptors differ, what the Phase 3 data shows, and where safety, regulation and cost fit into the wider picture today.
A quick note on scope. Retatrutide is still investigational and has no regulatory approval anywhere. Tirzepatide and semaglutide are licensed medicines that need a prescriber. Nothing here is medical advice. The materials supplied by Axiom Labs UK are for laboratory use only and not for human consumption, so treat this retatrutide vs tirzepatide vs semaglutide guide as an evidence summary for researchers, not a treatment recommendation. Please verify current regulatory status before relying on any figure.
Retatrutide vs Tirzepatide vs Semaglutide: How the Receptors Differ
Semaglutide Targets One Pathway
Semaglutide is a GLP-1 receptor agonist. It slows gastric emptying, raises insulin release when glucose is high and strengthens fullness signals in the brain. In the STEP 1 trial, it produced an average weight loss of 14.9% over 68 weeks. That result made it the reference point for every newer compound. In any retatrutide vs tirzepatide vs semaglutide review, semaglutide is the single-receptor baseline that the other two are measured against.
Tirzepatide Adds the GIP Receptor
Tirzepatide activates both GIP and GLP-1 receptors. The GIP signal appears to amplify insulin response and change how the body handles appetite and fat. In SURMOUNT-1, the 15 mg dose reached 22.5% average weight loss over 72 weeks. In the SURMOUNT-5 head-to-head trial, tirzepatide beat semaglutide, 20.2% against 13.7%. This is why the difference between tirzepatide and retatrutide is usually framed as two receptors versus three and why retatrutide vs tirzepatide vs semaglutide reads as a ladder.
Is Retatrutide a GLP-3?
No. GLP-3 is a popular nickname, not a recognized drug class. Retatrutide is a triple agonist acting on GIP, GLP-1, and glucagon receptors. So when people ask about GLP-1 vs GLP-3, or whether GLP-3 is the same as retatrutide, the accurate answer is that it includes GLP-1 activity but adds two more pathways. The glucagon signal is the new element, linked to higher energy expenditure and liver fat reduction in retatrutide vs tirzepatide vs semaglutide studies.
Retatrutide vs Tirzepatide vs Semaglutide: Trial Data Side by Side
| Compound | Receptors | Key trial result | Status (October 2026) |
| Semaglutide | GLP-1 | 14.9% (STEP 1, 68 weeks) | Approved |
| Tirzepatide | GIP + GLP-1 | 22.5% (SURMOUNT-1, 15 mg, 72 weeks) | Approved |
| Retatrutide | GIP + GLP-1 + glucagon | 28.3% (TRIUMPH-1, 80 weeks) | Investigational US filing planned for Q1 2027 |
Retatrutide vs Tirzepatide Weight Loss
On raw averages, retatrutide leads. TRIUMPH-1 reported 28.3% average weight loss at 80 weeks, and TRIUMPH-4 in people with knee osteoarthritis reported 28.7% at 68 weeks. Results were lower in harder populations: up to 20.8% in type 2 diabetes and up to 22.6% in severe obesity with cardiovascular disease. These cross-trial figures are indicative only, because populations and designs differ. A head-to-head study against tirzepatide is still ongoing, so the retatrutide vs tirzepatide vs semaglutide ranking is provisional.
Retatrutide vs Tirzepatide: Which Is Better?
Better depends on the question being asked. Retatrutide shows the highest average weight loss and strong liver fat data. Tirzepatide has years of real-world use, an approved label and head-to-head proof against semaglutide. Semaglutide has the strongest cardiovascular outcomes evidence in obesity, from the SELECT trial. The retatrutide vs tirzepatide vs semaglutide question cannot be settled with one number, and long-term retatrutide safety remains unproven for now. That nuance matters for anyone planning future studies.
Safety in Retatrutide vs Tirzepatide vs Semaglutide
Shared Gastrointestinal Effects
All three compounds share a similar gastrointestinal pattern. Nausea, vomiting, diarrhoea and constipation are most common during dose escalation and usually ease over several weeks. Published trial rates for nausea sit roughly between 30% and 45%, depending on compound and dose. Rarer risks such as gallbladder events and pancreatitis are monitored across the class. Tolerability shapes real-world use in retatrutide vs tirzepatide vs semaglutide as much as headline efficacy does.
The Retatrutide Dysesthesia Signal
A newer signal has appeared with retatrutide in Phase 3: dysesthesia, meaning abnormal skin sensations such as tingling or burning. In TRIUMPH-4, it was reported in about 21% of participants on 12 mg, against under 1% on placebo, and it was mostly mild. Stopping rates were also higher than for older agents. Regulators will examine this closely, which is one more reason the retatrutide vs tirzepatide vs semaglutide safety picture is still incomplete.
Regulation, Cost and Availability in the UK
Retatrutide vs Tirzepatide Cost
Cost comparisons are limited by status. Private UK prices for Mounjaro (tirzepatide) have been reported at roughly £133 to £330 a month depending on dose, and Wegovy (semaglutide) at roughly £130 to £295. Retatrutide has no price because it has no approval. Lilly plans a US filing in the first quarter of 2027, and no UK date has been set. A fair retatrutide vs tirzepatide vs semaglutide cost comparison must wait for a licence.
Why Combining Compounds Is Not Supported
Some readers ask about retatrutide and tirzepatide taken together. No trial has tested that combination, and both act on overlapping GIP and GLP-1 pathways, so stacking would add unknown risks. Licensed medicines belong under clinical supervision. Any retatrutide vs tirzepatide vs semaglutide discussion that suggests mixing compounds at home goes beyond the evidence and deserves real caution from every reader. Always rely on qualified clinical advice for prescribed treatment decisions.
Evaluating Research Peptides After the Retatrutide vs Tirzepatide vs Semaglutide Debate
Purity, Testing and Storage
If your laboratory references compounds in this class, quality documents matter more than marketing. Look for batch-specific certificates of analysis, HPLC purity data, clear labelling and careful cold-chain handling. Storage should follow your lab protocol. Our FAQs explain how Axiom Labs describes purity and product information, and our shipping policy covers tracked Royal Mail delivery. Good documentation matters in retatrutide vs tirzepatide vs semaglutide research, so ask suppliers to confirm batch numbers and testing dates.
Where to Browse Research Materials
Axiom Labs UK supplies research peptides strictly for laboratory use. You can browse the metabolic research category, including Cagrilintide 10mg, view the full research peptide range, or read more about Axiom Labs. For product questions, please contact our team. Retatrutide vs tirzepatide vs semaglutide moves fast, so check back often. Every product page lists specifications and research-use information, so you can review details before ordering, and orders are packed with care and dispatched from the UK.
Final Verdict on Retatrutide vs Tirzepatide vs Semaglutide
Retatrutide vs tirzepatide vs semaglutide shows a clear efficacy ladder: one receptor, two receptors, and three receptors, with rising average weight loss at each step. The trade-off is maturity. Semaglutide and tirzepatide are proven and prescribed today, while retatrutide is promising but investigational. Follow retatrutide vs tirzepatide vs semaglutide updates on our blog, rely on peer-reviewed data, and keep research materials strictly within laboratory use. Together, these steps keep the science accurate and the supply chain responsible.
FAQs About Retatrutide vs Tirzepatide vs Semaglutide
Is Retatrutide a Semaglutide?
No. Semaglutide is a single-receptor GLP-1 agonist developed by Novo Nordisk. Retatrutide is a different molecule from Eli Lilly that targets GIP, GLP-1 and glucagon receptors. They share GLP-1 activity, which is why people confuse them, but their structure, trial programmes and regulatory status are completely separate. That distinction sits at the heart of any retatrutide vs tirzepatide vs semaglutide comparison. Always confirm the manufacturer and the trial source behind any claim.
Is Retatrutide Approved in the UK?
No. Retatrutide has not been approved by the MHRA, FDA or any other regulator. Lilly has said it plans a US submission in the first quarter of 2027, and no UK filing date has been announced. Any product sold as retatrutide for human use before approval is unregulated, so treat such claims with serious caution and verify everything yourself before relying on any retatrutide vs tirzepatide vs semaglutide claim at this time.
Which Compound Shows the Highest Weight Loss?
In reported Phase 3 trials, retatrutide shows the highest average weight loss at about 28%, followed by tirzepatide at roughly 20% to 22% and semaglutide at about 14% to 15%. These figures come from different trials with different populations, so they are indicative only. A direct head-to-head result for retatrutide against tirzepatide is still awaited, and the retatrutide vs tirzepatide vs semaglutide order may change.
